|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu Z, Liu W and Gotlieb V: The rapidly
evolving therapies for advanced melanoma-Towards immunotherapy,
molecular targeted therapy, and beyond. Crit Rev Oncol Hematol.
99:91–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takeda K, Stagg J, Yagita H, Okumura K and
Smyth MJ: Targeting death-inducing receptors in cancer therapy.
Oncogene. 26:3745–3757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang S: The promise of cancer therapeutics
targeting the TNF-related apoptosis-inducing ligand and TRAIL
receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falschlehner C, Ganten TM, Koschny R,
Schaefer U and Walczak H: TRAIL and other TRAIL receptor agonists
as novel cancer therapeutics. Adv Exp Med Biol. 647:195–206. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bellail AC, Qi L, Mulligan P, Chhabra V
and Hao C: TRAIL agonists on clinical trials for cancer therapy:
The promises and the challenges. Rev Recent Clin Trials. 4:34–41.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kannan K, Holcombe RF, Jain SK,
Alvarez-Hernandez X, Chervenak R, Wolf RE and Glass J: Evidence for
the induction of apoptosis by endosulfan in a human T-cell leukemic
line. Mol Cell Biochem. 205:53–66. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kannan K and Jain SK: Oxidative stress and
apoptosis. Pathophysiology. 7:153–163. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee MW, Park SC, Yang YG, Yim SO, Chae HS,
Bach JH, Lee HJ, Kim KY, Lee WB and Kim SS: The involvement of
reactive oxygen species (ROS) and p38 mitogen-activated protein
(MAP) kinase in TRAIL/Apo2L-induced apoptosis. FEBS Lett.
512:313–318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lamy V, Bousserouel S, Gossé F, Minker C,
Lobstein A and Raul F: Lupulone triggers p38 MAPK-controlled
activation of p53 and of the TRAIL receptor apoptotic pathway in
human colon cancer-derived metastatic cells. Oncol Rep. 26:109–114.
2011.PubMed/NCBI
|
|
12
|
Park S, Cho DH, Andera L, Suh N and Kim I:
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by
regulating apoptosis-related proteins. Mol Cell Biochem. 383:39–48.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim H, Kim EH, Eom YW, Kim WH, Kwon TK,
Lee SJ and Choi KS: Sulforaphane sensitizes tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma
cells to TRAIL-induced apoptosis through reactive oxygen
species-mediated up-regulation of DR5. Cancer Res. 66:1740–1750.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Taniguchi H, Yoshida T, Horinaka M, Yasuda
T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T and Sakai
T: Baicalein overcomes tumor necrosis factor-related
apoptosis-inducing ligand resistance via two different
cell-specific pathways in cancer cells but not in normal cells.
Cancer Res. 68:8918–8927. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du J, Wu J, Fu X, Tse AK, Li T, Su T and
Yu ZL: Icairiside II overcomes TRAIL resistance of melanoma cells
through ROS-mediated downregulation of STAT3/cFLIP signaling.
Oncotarget. 7:52218–52229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Omar S, Lemonnier B, Jones N, Ficker C,
Smith ML, Neema C, Towers GH, Goel K and Arnason JT: Antimicrobial
activity of extracts of eastern North American hardwood trees and
relation to traditional medicine. J Ethnopharmacol. 73:161–170.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vardhini SR: Exploring the antiviral
activity of juglone by computational method. J Recept Signal
Transduct Res. 34:456–457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang XB, Zou CL, Duan YX, Wu F and Li G:
Activity guided isolation and modification of juglone from Juglans
regia as potent cytotoxic agent against lung cancer cell lines. BMC
Complement Altern Med. 15:3962015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu HL, Yu XF, Qu SC, Zhang R, Qu XR, Chen
YP, Ma XY and Sui DY: Anti-proliferative effect of Juglone from
Juglans mandshurica Maxim on human leukemia cell HL-60 by inducing
apoptosis through the mitochondria-dependent pathway. Eur J
Pharmacol. 645:14–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Liu A, Li Y, Zhao X, Lv S, Zhu W
and Jin Y: Anticancer activity and mechanism of juglone on human
cervical carcinoma HeLa cells. Can J Physiol Pharmacol.
90:1553–1558. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seshadri P, Rajaram A and Rajaram R:
Plumbagin and juglone induce caspase-3-dependent apoptosis
involving the mitochondria through ROS generation in human
peripheral blood lymphocytes. Free Radic Biol Med. 51:2090–2107.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu HL, Yu XF, Qu SC, Qu XR, Jiang YF and
Sui da Y: Juglone, from Juglans mandshruica Maxim, inhibits growth
and induces apoptosis in human leukemia cell HL-60 through a
reactive oxygen species-dependent mechanism. Food Chem Toxicol.
50:590–596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jha BK, Jung HJ, Seo I, Suh SI, Suh MH and
Baek WK: Juglone induces cell death of Acanthamoeba through
increased production of reactive oxygen species. Exp Parasitol.
159:100–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kischkel FC, Lawrence DA, Chuntharapai A,
Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment
of endogenous FADD and caspase-8 to death receptors 4 and 5.
Immunity. 12:611–620. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Daniel PT, Wieder T, Sturm I and
Schulze-Osthoff K: The kiss of death: Promises and failures of
death receptors and ligands in cancer therapy. Leukemia.
15:1022–1032. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mühlethaler-Mottet A, Bourloud KB,
Auderset K, Joseph JM and Gross N: Drug-mediated sensitization to
TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma
cells proceeds via activation of intrinsic and extrinsic pathways
and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Oncogene.
23:5415–5425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lacour S, Micheau O, Hammann A, Drouineaud
V, Tschopp J, Solary E and Dimanche-Boitrel MT: Chemotherapy
enhances TNF-related apoptosis-inducing ligand DISC assembly in
HT29 human colon cancer cells. Oncogene. 22:1807–1816. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prasad S, Kim JH, Gupta SC and Aggarwal
BB: Targeting death receptors for TRAIL by agents designed by
Mother Nature. Trends Pharmacol Sci. 35:520–536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhardwaj A and Aggarwal BB:
Receptor-mediated choreography of life and death. J Clin Immunol.
23:317–332. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song JJ and Lee YJ: Differential cleavage
of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation
of the MAPK superfamily. Cell Signal. 20:892–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
